^
    Back
    Association details:
    Biomarker:BRCA1 mutation
    Cancer:Hormone Receptor Positive Breast Cancer
    Drug:Talzenna (talazoparib) (PARP inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    ASCO 2018
    Title:

    Analysis of germline BRCA1/2 mutated (gBRCAmut) hormone receptor-positive (HR+) and triple negative breast cancer (TNBC) treated with talazoparib (TALA).

    Published date:
    05/16/2018
    Excerpt:
    Of 431 pts randomized, 241 had HR+ BC and 190 had TNBC. ORR for TALA was similar for the 2 groups: 61.8% for TNBC vs 63.2% for HR+. Duration of response median for TALA was longer for HR+ (6.8 months) compared to TNBC (4.3 months); both groups included a subset with a prolonged response to TALA...Talazoparib demonstrated improved PFS and ORR in pts both with gBRCAmut HR+ BC and TNBC.
    DOI:
    10.1200/JCO.2018.36.15_suppl.1070
    Trial ID:
    EMBRACA
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

    Excerpt:
    ...- Patients with only a VUS (Variant of Unknown Significance), or non-functional BRCA mutation, without a deleterious somatic BRCA 1 or 2 mutation will...
    Trial ID:
    NCT03990896